Huntsworth Health drafted in by Novartis

Pharma firm Novartis has taken on Huntsworth Health for its vaccines portfolio following a competitive pitch.

The agency has been hired to handle global medical and scientific comms for certain vaccine accounts managed from its office in Sienna.

Huntsworth Health's UK CEO Sandy Royden will head up the work across the portfolio. Account director Jennifer Chilver will work on medical and scientific education for the pre-launch vaccine used to prevent Japanese encephalitis, a viral disease transmitted by mosquitoes.

Huntsworth has also been taken on by Japanese pharma firm Daiichi Sankyo. It is charged with handling the pan-European PR activity for the firm's unnamed pre-launch hypertension drug. Huntsworth Health was awarded the account following a competitive pitch against undisclosed agencies.

The account will be run from the agency's Marlow medical comms division and will be headed up by associate divisional director of medical comms Annabelle Sandeman.

Separately, Huntsworth has won a NeoVista account, following work by Dorland Global, which handles the US side of the company. It will promote its Epiretinal Beta Radiation Therapy.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in